Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment… Read more
Andros Pharmaceuticals Co.,Ltd (6917) - Total Liabilities
Latest total liabilities as of June 2025: NT$38.58 Million TWD
Based on the latest financial reports, Andros Pharmaceuticals Co.,Ltd (6917) has total liabilities worth NT$38.58 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Andros Pharmaceuticals Co.,Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Andros Pharmaceuticals Co.,Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Andros Pharmaceuticals Co.,Ltd Competitors by Total Liabilities
The table below lists competitors of Andros Pharmaceuticals Co.,Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wam Research Ltd
AU:WAX
|
Australia | AU$17.07 Million |
|
WOWI Inc
PINK:WOWU
|
USA | $1.40 Million |
|
Aboitiz Power Corp
PSE:AP
|
Philippines | ₱308.45 Billion |
|
PCCW (TH3B.SG)
STU:TH3B
|
Germany | €84.86 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Andros Pharmaceuticals Co.,Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Andros Pharmaceuticals Co.,Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Andros Pharmaceuticals Co.,Ltd (2019–2024)
The table below shows the annual total liabilities of Andros Pharmaceuticals Co.,Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$47.31 Million | -18.49% |
| 2023-12-31 | NT$58.04 Million | +15.81% |
| 2022-12-31 | NT$50.12 Million | -2.89% |
| 2021-12-31 | NT$51.60 Million | -18.07% |
| 2020-12-31 | NT$62.99 Million | +5.17% |
| 2019-12-31 | NT$59.89 Million | -- |